Biogen (BIIB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Chair welcomed stockholders and introduced board members and executive team.
Independent auditor from PwC and inspector of elections were introduced.
Agenda and rules of conduct were posted on the virtual meeting site.
Board and executive committee updates
Chair announced her service as director and chair concludes at the end of the meeting.
Dr. Maria Freire will become the new chair of the board.
Board's experience and innovation highlighted as strengths for future oversight.
Shareholder proposals
Three proposals: election of 10 directors, ratification of PwC as auditor, and advisory vote on executive compensation.
Board recommended voting for all proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biogen
- Immunology and nephrology expansion, with key lupus and kidney assets, drive future growth.BIIB
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 saw 2% revenue growth, strong product gains, and Apellis acquisition set to lift EPS.BIIB
Q1 202629 Apr 2026 - 2025 saw robust growth, pipeline expansion, and strengthened governance, with all proposals backed.BIIB
Proxy filing28 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with online access.BIIB
Proxy filing28 Apr 2026 - $5.6B deal adds two FDA-approved therapies, accelerating nephrology and revenue growth.BIIB
M&A announcement2 Apr 2026 - Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials.BIIB
Stifel 2026 Virtual CNS Forum18 Mar 2026 - Felzartamab targets four kidney indications with phase III trials and a $2B+ AMR market opportunity.BIIB
Leerink Global Healthcare Conference 202610 Mar 2026 - Pipeline expansion and new launches drive growth, with major Alzheimer's and SMA catalysts ahead.BIIB
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs.BIIB
Piper Sandler Virtual Novel Targets in Immunology Symposium13 Feb 2026